Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

N: Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week pre-observation period followed by 24-week treatment period. Patients received placebo or edaravone i.v. infusion ove...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Amyotroph Lateral Scler Frontotemporal Degener
Main Authors: Abe, Koji, Itoyama, Yasuto, Sobue, Gen, Tsuji, Shoji, Aoki, Masashi, Doyu, Manabu, Hamada, Chikuma, Kondo, Kazuoki, Yoneoka, Takatomo, Akimoto, Makoto, Yoshino, Hiide
Formato: Artigo
Idioma:Inglês
Publicado em: Informa Healthcare 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4266079/
https://ncbi.nlm.nih.gov/pubmed/25286015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/21678421.2014.959024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados